Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17784075 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 19208126 | GLP-1 FORMULATIONS AND THEIR USES | Non-Final OA | Rose Pharma Inc. |
| 18028376 | METHODS FOR TARGET RELEASE FROM INTEIN COMPLEXES | Non-Final OA | MERCK PATENT GMBH |
| 18149982 | METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE | Non-Final OA | Eli Lilly and Company |
| 18995038 | USE OF COLLAGEN HYDROLYSATE AS AN ACTIVE INGREDIENT IN AMELIORATING SLEEP | Final Rejection | ROUSSELOT B.V. |
| 17416584 | NUTRITIONAL COMPOSITION FOR INDUCING A FEELING OF SATIETY, A BETTER SLEEP AND/OR LIMITING NOCTURNAL AWAKING IN INFANTS OR YOUNG CHILDREN | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18310702 | IMMUNOSUPPRESSIVE AGENTS | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 16650696 | METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17532578 | NANOPARTICLES COMPRISING NON-CLASSICAL MHC AND USES THEREOF | Non-Final OA | UTI Limited Partnership |
| 17760024 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | Non-Final OA | CENTRE LEON BERARD |
| 16762058 | Silk Alcohol Formulations | Non-Final OA | GIVAUDAN SA |
| 18032680 | NOVEL CXCR4-TARGETING COMPOUNDS | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 17773733 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 17311088 | HEPARANASE INHIBITORS AND THEIR USE AS ANTI-CANCER COMPOUNDS | Final Rejection | University of Iowa Research Foundation |
| 17788488 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF | Non-Final OA | HANMI PHARM. CO., LTD. |
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Final Rejection | HANMI PHARM, CO., LTD. |
| 17550702 | EDIBLE COMPOSITION FOR PROMOTING HAIR GROWTH AND DELAYING HAIR GRAYING | Final Rejection | Shanghai Lytone Biochemicals, Ltd. |
| 18028634 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | Non-Final OA | Saint Louis University |
| 18027331 | METHODS OF TREATING EYE DISORDERS | Non-Final OA | Apellis Pharmaceuticals, Inc. |
| 18491958 | INSECT NEUROPEPTIDES 5 | Final Rejection | Solasta Bio Limited |
| 18273962 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | Non-Final OA | BRIM Biotechnology, Inc. |
| 18335673 | ORAL OCTREOTIDE THERAPY IN COMBINATION WITH DIGOXIN OR LISINOPRIL | Final Rejection | Amryt Endo, Inc. |
| 18034407 | SITE-SELECTIVE MODIFICATION OF PROTEINS | Non-Final OA | Rigshospitalet |
| 17015500 | GLP-1 COMPOSITION FOR TREATING OBESITY AND WEIGHT MANAGEMENT | Final Rejection | SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION |
| 18038349 | PEPTIDE COMPOUND PRODUCTION METHOD | Non-Final OA | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION |
| 18303346 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Final Rejection | ALS THERAPY DEVELOPMENT INSTITUTE |
| 18191556 | COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME | Non-Final OA | Geltor, Inc. |
| 18245818 | METHOD OF REDUCING INTRAOCULAR PRESSURE | Non-Final OA | INVEX THERAPEUTICS LTD |
| 18181621 | NOVEL PROINSULIN GLARGINE AND METHOD FOR PREPARING INSULIN GLARGINE THEREFROM | Non-Final OA | Amphastar Nanjing Pharmaceuticals, Inc. |
| 18021660 | TISSUE-DERIVED MATRIKINE COMPOSITIONS AND METHODS THEREFOR | Non-Final OA | XYLYX BIO, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy